The global Crohn’s disease market is estimated to grow at a significant CAGR of 4.2% during the forecast period. Crohn's disease inflammation spreads into the layers of affected bowel tissues. Crohn's disease is painful and may lead to life-threatening complications. Anti-inflammatory drugs, immune system suppressors, antibiotics, anti-diarrheal medications, pain relievers, iron supplements are also used during the treatment and recovery of Crohn's disease. Crohn’s & Colitis Foundation launched a new open access journal in order to provide information to more than 3 million Americans living with IBD. Such platforms increase awareness among the population that further contribute to the growth of the market. 

 The market for Crohn’s disease is growing due to the increasing prevalence of Chron’s disease across the globe. The increasing prevalence of IBD results in the need for research for the prevention of (Inflammatory Bowel Disease) IBD and innovations in healthcare systems to manage this complex and costly disease. Crohn’s disease is an IBD type that causes chronic inflammation and damage in the gastrointestinal (GI) tract. Further, funding also leads to improving the quality of healthcare facilities. In 2018, Crohn’s & Colitis Foundation has received a $3.3 million grant from The Leona M. and Harry B. Helmsley Charitable Trust to support IBD Qorus, the Foundation’s flagship quality of care program. Further, in 2018, Patient-Centered Outcomes Research Institute (PCORI) funded $2.4 million to Crohn’s & Colitis Foundation in order to study the comparative effectiveness of biologic or small molecule therapies in IBD. Such funding programs in order to increase awareness and R&D are contributing to market growth.  

 Segmental Outlook  

The global Crohn’s disease market is classified on the basis of treatment type including surgery and anti-inflammatory drugs. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs.

Global Crohn’s disease Market Share by Treatment Type, 2018(%)

Global Crohn’s disease market to be driven by Anti- Inflammatory Drug Administration

The anti-inflammatory drug administration segment is projected to have a considerable share in the market. Anti-inflammatory drugs are usually the first step in the treatment of Crohn’s disease. The major objective of drug treatment is to reduce inflammation in the gut and provide relief from Crohn’s disease symptoms. When the condition is under control, the doctors most often prescribe drugs to achieve remission and prevent relapse. This is referred to as maintenance treatment. The medication depends on the affected area of the colon. Some of these medications used for adults and children suffering from Crohn’s disease. Crohn’s disease medication can usually reduce inflammation and promote intestinal healing. This, in turn, results in achieving remission that signifies long-term symptom relief.

Regional Outlook 

Geographically, the global Crohn’s disease market is further classified into North America, Europe, Asia-Pacific and the Rest of the World. Asia-Pacific is estimated to have considerable market growth in the global market during the forecast period. The market in Asia-Pacific is largely driven by the substantial healthcare expenditure in the major economies of the region, shifting lifestyle among adults and rapid urbanization in the emerging economies such as India and China. With the substantial healthcare expenditure, government services are improving rapidly in the region, thus, it ensures better availability of treatment for various diseases including IBD such as Crohn’s disease.

Global Crohn’s disease Market Growth, by Region 2019-2025

North America to hold a considerable share in the global Crohn’s disease market

North America is projected to have a significant market share in the global market owing to the well-established healthcare industry and sufficient funding for Crohn’s disease treatment and research. Additionally, the prevalence of smoking and the presence of major market players in the global Crohn’s disease market is supporting North America’s market share. A significant number of cigarette smoking people have been observed in the US which has led to the development of risk of Crohn’s disease across the country. According to CCFA, Crohn’s disease is more likely to be developed around twice more by active smokers than non-smokers. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease. 

Market Players Outlook

The key players in the Crohn’s disease market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include Abbott Laboratories, AbbVie Inc., Allergan PLC,  Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Pfizer Inc., Takeda Pharmaceutical Co., Ltd. and others. These market players adopt various strategies such as product launch, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. For instance, In December s2019 Takeda pharmaceutical Co., Ltd. partnered with MiTest Health LLC to launch disease risk prediction tool for Crohn’s Disease Management 

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Crohn’s disease market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.